Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;72(2):e31456.
doi: 10.1002/pbc.31456. Epub 2024 Nov 24.

The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related

Dan Geller  1   2 , Ivan Budnik  3 , Tlalit Barhod  1 , Omri Cohen  1   2 , Tamar Brutman-Barazani  1   2 , Orly Efros  1   2 , Aharon Lubetsky  1 , Shadan Lalezari  1 , Sarina Levy-Mendelovich  1   2 , Gili Kenet  1   2 , Assaf A Barg  1   2
Affiliations

The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related

Dan Geller et al. Pediatr Blood Cancer. 2025 Feb.

Abstract

Introduction: Hemophilia A (HA) therapy poses a significant healthcare burden. In recent years, emicizumab has been approved for prophylaxis. The current study explores the impact of transitioning to emicizumab on emergency department (ED) visits and hospitalizations in pediatric and adult HA patients.

Methods: Data of HA patients transitioned to emicizumab at the Israeli National Hemophilia Center was retrospectively analyzed. Demographic information, inhibitor status, treatment duration, number, and reasons of ED visits and hospitalizations were assessed.

Results: Overall, transitioning to emicizumab significantly reduced ED visits and hospitalizations. While children experienced a significant reduction in both ED visits and hospitalizations, adults showed no statistically significant change. Post-emicizumab initiation, main reasons for ED visits among children shifted from prophylactic treatment and central line-associated complications to injury-related incidents.

Conclusions: This real-world analysis demonstrates a substantial decrease in ED visits and hospitalizations, following emicizumab prophylaxis in HA patients. However, this improvement was age dependent as it was observed only among children. Further prospective studies evaluating this aspect may shed light on these findings.

Keywords: Emergency Department visits; Emicizumab; Healthcare; Hemophilia; Hospitalizations.

PubMed Disclaimer

References

    1. Zwagemaker, Gouw S. C., Jansen J. S., Vuong C., Coppens M., Hu Q., et al., “Incidence and Mortality Rates of Intracranial Hemorrhage in Hemophilia: A Systematic Review and Meta‐analysis,” Blood 138, no. 26 (2021): 2853–2873.
    1. Barg A., Livnat T., and Kenet G., “Inhibitors in Hemophilia: Treatment Challenges and Novel Options,” Seminars in Thrombosis and Hemostasis 44, no. 06 (2018): 544–550.
    1. Blair H. A., “Emicizumab: A Review in Haemophilia A,” Drugs 79, no. 15 (2019): 1697–1707.
    1. Mahlangu J., Iorio A., and Kenet G., “Emicizumab state‐of‐the‐art Update,” Haemophilia 28, no. S4 (2022): 103–110.
    1. Young G., Liesner R., Chang T., Sidonio R., Oldenburg J., Jiménez‐Yuste V., et al., “A Multicenter, Open‐Label Phase 3 Study of Emicizumab Prophylaxis in Children With Hemophilia A With Inhibitors,” Blood 134, no. 24 (2019): 2127–2138.

MeSH terms

LinkOut - more resources